A nUtrition and Lifestyle Intervention in Patients With Pulmonary Arterial HypertensIon

NCT ID: NCT05318950

Last Updated: 2022-04-08

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

40 participants

Study Classification

INTERVENTIONAL

Study Start Date

2019-10-20

Study Completion Date

2022-02-16

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Rationale: Nutrition and lifestyle interventions are currently not implemented in usual clinical care of PAH-patients. Mainly because there is little known on the relation between pathology, nutrition and lifestyle. Patients who suffer from Pulmonary Arterial Hypertension feel insecure about their nutrition and lifestyle. The investigators hypothesize that an intervention on nutrition and lifestyle can improve the patients' quality of life.

Objective: To explore the effect of a nutrition and lifestyle intervention on quality of life for patients suffering from PAH.

Study design: Investigator initiated intervention study with control group. Study population: investigators aim to include 70 patients (18 - 80 years) with idiopathic, hereditable or drug related PAH, who have been stable for at least three months and are self-sufficient and/or have a family who's willing to participate in the lifestyle changes.

Intervention (if applicable): Nutritional status, - education, - intervention and - compliance.

Main study parameters/endpoints: This is an intervention study in which the investigators will asses the effect of a nutrition and lifestyle intervention on quality of life measured by SF-36 overall outcome with a significant difference of 6.35.

Nature and extent of the burden and risks associated with participation, benefit and group relatedness: The burden for the patient exists of 12 extra visits to the hospital and contact moments, over a period of 11 months, as well compliance to the diet and lifestyle. There is minimal risk in participation.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Baseline nutritional assessment

Nutritional education:

8 online lessons containing information about nutrition, lifestyle and general health with complementary tips regarding PH. All participants recieve workbook with assignments.

Nutritional intervention:

Group A: MedDASH diet (55% carbohydrates, 25% amino acids, 20% fatty acids) Group B: MedDASHfat diet (10% carbohydrates, 25% amino acids, 65% fatty acids) Control group: no diet.

Follow-up:

Patients in intervention arm followed for a period of 6 months to assess compliance.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Pulmonary Arterial Hypertension

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

SEQUENTIAL

Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Participants
Randomisation control and E-learning Randomisation Diet A and B

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Control

No intervention

Group Type NO_INTERVENTION

No interventions assigned to this group

E-learning

E-learning: 8 lessons about nutrition and lifestyle

Group Type EXPERIMENTAL

E-learning

Intervention Type BEHAVIORAL

8 lessons about nutrition and lifestyle

Diet A

MedDASH diet (55% carbohydrates, 25% amino acids, 20% fatty acids)

Group Type EXPERIMENTAL

E-learning

Intervention Type BEHAVIORAL

8 lessons about nutrition and lifestyle

Diet

Intervention Type DIETARY_SUPPLEMENT

Diet A: MedDASH diet (55% carbohydrates, 25% amino acids, 20% fatty acids) Diet B: MedDASHfat diet (10% carbohydrates, 25% amino acids, 65% fatty acids)

Diet B

MedDASHfat diet (10% carbohydrates, 25% amino acids, 65% fatty acids)

Group Type EXPERIMENTAL

E-learning

Intervention Type BEHAVIORAL

8 lessons about nutrition and lifestyle

Diet

Intervention Type DIETARY_SUPPLEMENT

Diet A: MedDASH diet (55% carbohydrates, 25% amino acids, 20% fatty acids) Diet B: MedDASHfat diet (10% carbohydrates, 25% amino acids, 65% fatty acids)

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

E-learning

8 lessons about nutrition and lifestyle

Intervention Type BEHAVIORAL

Diet

Diet A: MedDASH diet (55% carbohydrates, 25% amino acids, 20% fatty acids) Diet B: MedDASHfat diet (10% carbohydrates, 25% amino acids, 65% fatty acids)

Intervention Type DIETARY_SUPPLEMENT

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Diagnosis of idiopathic PAH, hereditable PAH or drug related PAH
* Age between 18 and 80
* NYHA II or III and stable for at least 3 months, determined by a stable 6minute walk test with a difference of \<10%.
* Self-sufficient and/or compliance from partner and/or family
* Creatinine \> 30 ml/min
* Able to understand and willing to sign the Informed Consent Form

Exclusion Criteria

* \- Pregnant subjects
* Fat percentage \< 10% \> 50 %
* One or more of the following comorbidities: diabetes mellitus type one or two, clinically relevant thyroid disease
* Known history of noncompliance considering therapies
Minimum Eligible Age

18 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Reinier de Graaf Groep

OTHER

Sponsor Role collaborator

Janssen-Cilag B.V.

INDUSTRY

Sponsor Role collaborator

Amsterdam UMC, location VUmc

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

A. Vonk Noordegraaf

Prof. Dr.

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Anton Vonk Noordegraaf, prof. dr.

Role: PRINCIPAL_INVESTIGATOR

VUMC

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

VU medical center

Amsterdam, North Holland, Netherlands

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Netherlands

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

NL66484.029.18

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.